Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eton Pharmaceuticals, Inc. - Common Stock (NQ:ETON)

19.57 +0.64 (+3.38%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eton Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
A Glimpse Into The Expert Outlook On Eton Pharmaceuticals Through 4 Analysts
Via Benzinga
Eton Pharmaceuticals Reports First Quarter 2025 Financial Results
From Eton Pharmaceuticals
Via GlobeNewswire
A Look Ahead: Eton Pharmaceuticals's Earnings Forecast
Via Benzinga
Eton Pharmaceuticals to Report First Quarter 2025 Financial Results on Tuesday, May 13, 2025
From Eton Pharmaceuticals
Via GlobeNewswire
The Analyst Verdict: Eton Pharmaceuticals In The Eyes Of 5 Experts
Via Benzinga
Analyst Expectations For Eton Pharmaceuticals's Future
Via Benzinga
Earnings Scheduled For November 12, 2024
Via Benzinga
Earnings Outlook For Eton Pharmaceuticals
Via Benzinga
Earnings Scheduled For May 13, 2025
Via Benzinga
Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution)
From Eton Pharmaceuticals
Via GlobeNewswire
Evaluating ETON PHARMACEUTICALS INC (NASDAQ:ETON) using Mark Minervini’s winning stock formula
A fundamental and technical analysis of (NASDAQ:ETON): Is ETON PHARMACEUTICALS INC (NASDAQ:ETON) suited for high growth investing? 
Via Chartmill
Eton Pharmaceuticals Out-Licenses International Rights to Increlex®
Esteve Pharmaceuticals, S.A. will commercialize Increlex in all markets outside the U.S. 
From Eton Pharmaceuticals
Via GlobeNewswire
5 Analysts Assess Eton Pharmaceuticals: What You Need To Know
Via Benzinga
Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results
From Eton Pharmaceuticals
Via GlobeNewswire
Earnings Scheduled For March 18, 2025
Via Benzinga
Eton Pharma Plans FDA Filing For ET-600 Oral Desmopressin Next Month, Eyes 2026 Launch
Eton Pharmaceuticals' ET-600 met bioequivalence standards in a study, with an FDA filing planned for April 2025 and a potential launch in early 2026. 
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600
From Eton Pharmaceuticals
Via GlobeNewswire
Rocket Companies, Novo Nordisk And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Eton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals Announces Commercial Launch of Galzin® (zinc acetate) Capsules
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals Expands Patent Portfolio with Issuance of New U.S. Patent for ET-600
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals Announces Extension of PDUFA Goal Date for ET-400
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin®
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection)
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals Announces Final Readout of PKU GOLIKE® Clinical Trial
Clinical Trial Demonstrates Clinical and Statistical Improvement in Metabolic Control During Prolonged Fasting in PKU Patients - Results Expected to Promote Awareness and Adoption of PKU GOLIKE® 
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension)
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals Reports Third Quarter 2024 Financial Results
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals Awarded Second Patent for ET-400 (Hydrocortisone Oral Solution)
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
From Eton Pharmaceuticals
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.